Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Genomic Health Inc (GHDX)

Genomic Health Inc (GHDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,384,583
  • Shares Outstanding, K 37,588
  • Annual Sales, $ 394,110 K
  • Annual Income, $ 25,680 K
  • 60-Month Beta 0.90
  • Price/Sales 6.09
  • Price/Cash Flow 44.07
  • Price/Book 6.83
Trade GHDX with:
  • Price/Earnings ttm 44.67
  • Earnings Per Share ttm 1.08
  • Most Recent Earnings 0.42 on 07/29/19
  • Next Earnings Date 11/12/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 0.40
  • Number of Estimates 5
  • High Estimate 0.48
  • Low Estimate 0.34
  • Prior Year 0.35
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.74 +1.12%
on 11/07/19
71.50 -11.27%
on 10/15/19
-5.37 (-7.80%)
since 10/07/19
3-Month
62.74 +1.12%
on 11/07/19
77.00 -17.61%
on 08/30/19
-9.73 (-13.30%)
since 08/07/19
52-Week
50.77 +24.96%
on 06/12/19
90.18 -29.65%
on 11/08/18
-26.74 (-29.65%)
since 11/07/18

Most Recent Stories

More News
Personalis Announces Changes to its Board of Directors

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has appointed Dr. Woodrow (Woody) Myers to its Board of Directors and to the...

ESRX : 92.33 (-3.62%)
GHDX : 63.44 (-0.69%)
PSNL : 23.09 (-1.32%)
Enormous Growth of Global Prostate Cancer Diagnostics Market | Including Top Players like Abbott, MDxHealth, Genomic Health, 3D Signatures, OPKO Health, INC., Siemens Healthcare GmbH, DiaSorin S.p.A, F. Hoffman La Roche Ltd

 

DXD.VN : 0.040 (unch)
GHDX : 63.44 (-0.69%)
OPK : 4.20 (+1.69%)
SIEGY : 82.8900 (-0.54%)
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

GHDX : 63.44 (-0.69%)
EXAS : 127.14 (-0.67%)
Prostate Cancer Diagnostics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The research report on Prostate Cancer Diagnostics provide insights on growth-influencing factors such as industry trends, understanding consumer demands, product application, competitive landscape, pricing...

DXD.VN : 0.040 (unch)
A : 131.97 (-0.75%)
BIOC : 4.51 (+2.27%)
CGIX : 4.61 (-2.33%)
FMI : 136.95 (-0.04%)
GHDX : 63.44 (-0.69%)
OPK : 4.20 (+1.69%)
SIEGY : 82.8900 (-0.54%)
Cancer/Tumor Profiling Market Development, Future Trends and Indepth Analysis Research | Illumina Inc, Qiagen N.V.

A consciously conceived and designed business intelligence report titled Global  by Manufacturers, Type, and Application, Forecast to 2029 by discloses a succinct analysis of the regional spectrum,...

AGCO : 150.65 (+1.45%)
GHDX : 63.44 (-0.69%)
HTGM : 4.81 (+0.63%)
ILMN : 398.07 (-1.26%)
QGEN : 51.18 (-1.63%)
RTN : 116.70 (-0.22%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Breast Cancer Diagnostics Market to Reach USD 8,738.9 Million By 2027 | Reports And Data

Growing awareness for early detection of breast cancer is one of the significant factors influencing the market growth.

BCR : 331.24 (-0.59%)
GHDX : 63.44 (-0.69%)
HOLX : 75.01 (-0.85%)
NSTG : 71.68 (-3.86%)
COVID-19 Impact On Global Prostate Cancer Diagnostics Market Recovery Analysis,Revenue,Supply Demand,Investment And Forecast 2027

The global is studied in detail in the new report on Qualiket Research. The new report studies the Prostate Cancer Diagnostics Market by profiling its major driving factors and restraining factors, compiling...

DXD.VN : 0.040 (unch)
GHDX : 63.44 (-0.69%)
OPK : 4.20 (+1.69%)
SIEGY : 82.8900 (-0.54%)
Genomic Health I Shares Down 8.9% Since SmarTrend's Sell Call (GHDX)

SmarTrend identified a Downtrend for Genomic Health I (NASDAQ:GHDX) on September 27th, 2019 at $69.60. In approximately 14 months, Genomic Health I has returned 8.85% as of today's recent price of $63.44....

GHDX : 63.44 (-0.69%)
8.9% Return Seen to Date on SmarTrend Genomic Health I Call (GHDX)

SmarTrend identified a Downtrend for Genomic Health I (NASDAQ:GHDX) on September 27th, 2019 at $69.60. In approximately 13 months, Genomic Health I has returned 8.85% as of today's recent price of $63.44....

GHDX : 63.44 (-0.69%)
Global Prostate Cancer Diagnostics Market : Key Trends, Growth Analysis by Top Countries Data and Forecast to 2024 with Top Key Players Abbott, MDxHealth, Genomic Health, 3D Signatures & OPKO Health,

DXD.VN : 0.040 (unch)
GHDX : 63.44 (-0.69%)
OPK : 4.20 (+1.69%)
SIEGY : 82.8900 (-0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 65.41
1st Resistance Point 64.43
Last Price 63.44
1st Support Level 62.60
2nd Support Level 61.75
3rd Support Level N/A

See More

52-Week High 90.18
Fibonacci 61.8% 75.13
Fibonacci 50% 70.47
Fibonacci 38.2% 65.82
Last Price 63.44
52-Week Low 50.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar